Stockreport

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Sarepta Therapeutics, Inc.  (SRPT) 
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF In early clinical results, Sarepta’s avß6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1Company to [Read more]